Oncotarget

Research Papers:

Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma

Ahmed Omar Kaseb _, Manal Hassan, Sahin Lacin, Reham Abdel-Wahab, Hesham M. Amin, Ahmed Shalaby, Robert A. Wolff, James Yao, Asif Rashid, Bharathi Vennapusa, Janine Feng and Toshihiko Ohtomo

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:69916-69926. https://doi.org/10.18632/oncotarget.12066

Metrics: PDF 1129 views  |   HTML 1109 views  |   ?  


Abstract

Ahmed Omar Kaseb1, Manal Hassan1, Sahin Lacin1,3,*, Reham Abdel-Wahab1,4,*, Hesham M. Amin2, Ahmed Shalaby1, Robert A. Wolff1, James Yao1, Asif Rashid2, Bharathi Vennapusa5, Janine Feng5, Toshihiko Ohtomo6

1Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

2Division of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

3Department of Medical Oncology, Hacettepe University, Medical Faculty, Ankara, Turkey

4Department of Clinical Oncology, Assiut University Hospital, Assiut, Egypt

5Ventana Medical Systems, Inc., Tucson, Arizona, USA

6Chugai Pharmaceutical Co., LTD., Tokyo, Japan

*These authors contributed equally to this work

Correspondence to:

Ahmed Omar Kaseb, email: akaseb@mdanderson.org

Keywords: hepatocellular carcinoma, glypican-3, immunohistochemistry

Received: June 16, 2016     Accepted: September 05, 2016     Published: September 16, 2016

ABSTRACT

Hepatocellular carcinoma (HCC) is one of the most deadly cancers worldwide. In patients with HCC, histopathogical differentiation is an important indicator of prognosis; however, because determination of HCC differentiation is difficult, the recently described immunohistochemical (IHC) marker glypican3 (GPC3) might assist in HCC prognostication.The goal of our study was to investigate GPC3’s IHC staining pattern and define the relationship between its expression and patients’ clinicopathologic features and overall survival. We retrieved clinical parameters from 101 pathologically diagnosed HCC patients’ medical records and classified these patients into 4 clinical score categories (0–3) based on increasing GPC3 staining intensity and the percentage of stained tumor cells in their resection and biopsy specimens. Histopathological samples were well, moderately, and poorly differentiated in 33, 22, and 12 patients, respectively, and the GPC3 expression rate was 63%, 86%, and 92%,respectively. The median overall survival was 49.9 months (confidence interval (CI): 35.3–64.6 months) for clinical scores 0–1 and 30.7 months (CI: 19.4–41.9 months) for clinical scores 2–3. This difference was not statistically significant (P = .06) but showed a strong trend. In conclusion, a greater GPC3 expression is associated with a worse HCC prognosis and may be a promising prognostic marker.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 12066